Replies to post #39645 on Manzo Pharmaceuticals Inc. (MNZO)

[DragonBear]

If the MDIN ever acts on their patent license, MNZO would reap the royalty rewards

No, at the time MDIN was awarded the license, the patent was held by Sharma & Kenny. With the royalties paid to those two. There's no evidence Celpro ever held the patent. Only that a condition of MDIN being granted the license, was a payment of 400M shares to Celpro.

MNZO only became the patent holder in Dec 2015. The terms of the assignment being unknown. MNZO would not collect royalties on past licenses granted by Sharma&Kenny.

One had the set up of:

The MDIN scam using the wonder bug license to pump their own stock. Sharma&Kenny benefit by the stock Celpro holds, and can later dump. Apparently a dump the SEC has issues with.

Simultaneously starts up the MNZO scam. Where this time Kenny gets scam stock for patent rights. Then in Dec Kenny & fiends decide to aim high with a Form D offering. Oops forgot to assign patent rights to MNZO - so they do so in Dec 2015.

It was a good set up, until the SEC arrived.

[samsamsamiam]

So now his excuse is he didn't read the final agreement????
WOW. He is in over his head and I am sure the SEC knows it.
Hope he has a good lawyer!

BTW - We are talking about the very same patent here - the one they pumped for MDIN as the actual patent and now MNZO who has taken out a trade name for it.

http://manzopharma.com/lacto-relief-for-people-with-la-ctose-intolerance/lacto-relief-patent/



There will be no competing products - as neither company has a pot to piss in and that Smitherman guy doesn't appear to have done much - especially for what they paid him. Not to mention he can be found no where on any FINRA registered funding portal list that I looked at nor on Broker check where he would have had to be listed. His name appears as author on that offering - not sure what his experience would have been to put that together - as he is not licensed with FINRA - although I suspect Ray Barton and his crew had a hand in it.

Arthur Smitherman – Secretary Treasurer
Principal occupations: Life time entrepreneur, working primarily in the Transportation business. Operated The Business Network and has related experience, education, licenses and qualifications in the Securities, Insurance and Financial Services Industries. He owns and operates directprivateoffers.com, a FINRA registered funding portal. He is presently licensed and works as a Mortgage Agent; and may be licensed and work as an Insurance Agent and/or Financial Advisor at any given time. He owns and operates the FINRA registered funding portal: directprivateoffers.com. He will devote such time as necessary to make Manzo Pharmaceuticals Inc. successful.

If someone else can check about the Finra registered funding portal that would be good. Otherwise this guy is probably going to be asked a few questions as well. But he definitely is NOT registered with FINRA when I checked last week.


Ken Manzo was very much aware of what was going on. The press release clearly mentions they closed a deal with the owners of the patent. And those owners are Jay Sharma and Ken Manzo.

http://www.prnewswire.com/news-releases/northstar-acquires-a-new-and-exciting-patent-license-in-a-multi-billion-dollar-industry-209327661.html



HOLBROOK, N.Y., May 29, 2013 /PRNewswire/ -- Northstar Global Business Services, Inc. Symbol (OTCPink: MDIN), today announced that after lengthy negotiations, it has closed a deal with the owners, and inventors of one of the most exciting health related patented processes in the US today. The patent, titled: "Method of treating lactose intolerance using genetically engineered bacteria," covers a process for the creation of a product that when ingested, has been shown to have the potential of completely alleviate the symptoms of lactose intolerance. The product, developed in partnership with Celprogen, Inc. by it's co-inventor, pharmacist Kenneth Manzo, showed that when tested in laboratory rats, their intolerance for lactose-based foods disappeared for up to three months without taking additional doses of the product.









In that Reg D offering they said
" On June 11, 2014, 4,000,000 Series A Preferred shares of the Company were issued in exchange for all units of Manzo Pharmaceuticals, LLC. (“MPL”). The Company operates as the parent company and MPL as the subsidiary. As part of the acquisition, Kenneth Manzo was appointed Chief Executive Officer and Chairman of the Company. Kenneth Manzo organized MPL on November 12, 2013 under the laws of the State of Pennsylvania. Mr. Manzo is a registered pharmacist and graduated from St. John’s University in Queens, New York in 1991 with a degree in pharmaceutical science. "











It appears some months later they upped the A/S common and preferred shares - which are not reflected on the OTC site or filings.




Wyoming shows after Dec 2015 they have A/S 5,000,000,000

common and 1,000,000,000 preferred. Something that is not reflected on OTC and also in the filings they used the old number of 1.9 billion.






Common Shares

5,000,000,000

Common Par Value

$0.001

Preferred Shares

1,000,000,000

Preferred Par Value

$0.001



https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=108194067094219057175103048254161232094048197154

see history and restated articles dated Dec 2015.







=====

Ken Manzo is way in over his head - and I have no doubt Ray Barton will be sure he is the one that gets thrown under the bus. He needs to keep his yapper shut. And get a good lawyer. A lawyer that understands when the SEC asks you questions they are not NIT PICKING!!!!